Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Evangelia Razis(Hygeia Hospital), George Fountzilas(Hellenic Cooperative Oncology Group), G. Karkavelas(Aristotle University of Thessaloniki), Sofia Karanastasi(Aristotle University of Thessaloniki), Mei‐Jun Zhu(Washington State University), Stephanos Labropoulos(Aristotle University of Thessaloniki), David Song(New York Hospital Queens), Jeremy L. Norris(Aristotle University of Thessaloniki), Michael Torrens(Aristotle University of Thessaloniki), Jonathan A. Fletcher(Harvard University), Thea Kalebic(Aristotle University of Thessaloniki), Anna Kalogera‐Fountzila(Aristotle University of Thessaloniki), Panayotis Selviaridis(Aristotle University of Thessaloniki)
Cited by 103
Related Papers
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647
Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma
|American Journal Of Pathology|2001|639